The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Investigating the severity of Teliso-V-induced neuropathy in NSCLC
Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, comments on the median onset of peripheral sensory neuropathy in patients treated with the MMA-based payload telisotuzumab vedotin (Teliso-V), stating that it occurs around 103 days after initiation of the drug, which is significantly longer than typical taxane-based chemotherapy-induced neuropathies. Patients with grade two or more sensory neuropathies exhibit higher objective response rates and longer progression-free survival compared to those without such neuropathies, suggesting a favorable balance between safety and efficacy for Teliso-V. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So basically we have the MMA-based payload Teliso-V showed that the median onset of the peripheral sensory neuropathy is around 103 days. That means three months later the initiation of the drug. That means it’s pretty much pretty longer than the usual taxane-based chemotherapy-based sensory neuropathies and just means that this agent is very greatly affecting the patients who are experiencing a higher efficacy is uh experiencing a higher rate for the peripheral sensory neuropathies based on such evaluation we evaluated objective response and also the progression-free survival of this agent and in the patients with or without grade two or more sensory neuropathies when we evaluated that when the patients having the grade two or more sensory neuropathy the objective response is much higher and also the progression-free survival is much longer it means vice versa the when the patients who are experiencing a higher efficacy like the objective response and also the longer PFS is suffered by the taxane-based sensory neuropathy but But that said, because the patients are enjoying the efficacy of time, the safety and efficacy profile balance is very good...
So basically we have the MMA-based payload Teliso-V showed that the median onset of the peripheral sensory neuropathy is around 103 days. That means three months later the initiation of the drug. That means it’s pretty much pretty longer than the usual taxane-based chemotherapy-based sensory neuropathies and just means that this agent is very greatly affecting the patients who are experiencing a higher efficacy is uh experiencing a higher rate for the peripheral sensory neuropathies based on such evaluation we evaluated objective response and also the progression-free survival of this agent and in the patients with or without grade two or more sensory neuropathies when we evaluated that when the patients having the grade two or more sensory neuropathy the objective response is much higher and also the progression-free survival is much longer it means vice versa the when the patients who are experiencing a higher efficacy like the objective response and also the longer PFS is suffered by the taxane-based sensory neuropathy but But that said, because the patients are enjoying the efficacy of time, the safety and efficacy profile balance is very good.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
